pipeline: archive 1 source(s) post-merge

Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>

inbox/archive/health/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.md

@@ -0,0 +1,61 @@
+---
+type: source
+title: "Semaglutide Patent Expires India March 20 2026 — 50+ Generic Brands Launch, 50-60% Price Drop"
+author: "STAT News / Medical Dialogues India / MedDataX"
+url: https://www.statnews.com/2026/03/17/generic-semaglutide-india-bmi-obesity-definition/
+date: 2026-03-17
+domain: health
+secondary_domains: []
+format: news analysis
+status: processed
+priority: high
+tags: [glp1, semaglutide, generics, price-compression, india, patent-expiry, ozempic, wegovy]
+---
+
+## Content
+
+**Patent expiration timeline:**
+- India: March 20, 2026 (TODAY — generics launch March 21)
+- Also expiring in 2026: Canada, Brazil, Turkey, China
+- US patents: 2031-2033 (last firewall)
+- University of Liverpool analysis: production cost as low as $3/month ($28-140/year)
+
+**India market specifics (as of March 20, 2026):**
+- 50+ brands filed for Indian market
+- Current price: ₹8,000-16,000/month (~$95-190)
+- Expected generic launch price: 50-60% below branded (₹3,000-5,000/month, ~$36-60)
+- Named companies: Dr. Reddy's Laboratories, Cipla, Sun Pharma (Noveltreat, Sematrinity), Zydus (Semaglyn), OneSource Specialty Pharma
+- Sun and Zydus launching prefilled pens at ~50% below branded
+- Analysts project 90% price reduction over 5 years from competition
+
+**Canada timeline:**
+- Generic Ozempic waitlist already forming (Felix Health)
+- Price from ~$400 CAD/month (branded) to projected $60-100 CAD/month with competition
+- Some projections: under $100 CAD within 12 months of generic launch
+
+**Oral Wegovy context (from March 19 session):** Already launched at $149-299/month (January 2026), vs. $1,300+ injectable branded. Combined with international generics, the price compression is multi-vector.
+
+**STAT News March 17 story**: Specifically covers India's GLP-1 launch and the BMI/obesity definition debate. Indian medical community is questioning whether GLP-1s are appropriate given different BMI thresholds (lower BMI associated with metabolic risk in South Asian populations). This is a separate but interesting access/appropriateness story.
+
+**University of Liverpool study:** Production cost analysis shows semaglutide COULD be produced for under $3/month. Market prices will be higher due to distribution, regulatory, and profit margins, but $28-140/year (injectable) is the theoretical price floor within 5-10 years.
+
+## Agent Notes
+
+**Why this matters:** This directly updates one of the KB's existing explicit claims: "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035." That "inflationary through 2035" conclusion was based on US-patent-protected pricing. The international patent cliff is not a 2030+ event — it's happening NOW (India: March 20, 2026). The inflection point for non-US markets has arrived.
+
+**What surprised me:** The 50+ Indian brand figure. This isn't a "2-3 generic competitors" situation — it's a price war with 50+ entrants. The Canadian, Brazilian, and Chinese situations are separate and add further price pressure. The $3/month production cost is jaw-dropping — the manufacturing economics support near-commodity pricing within 5 years.
+
+**What I expected but didn't find:** OBBBA/work requirements intersection with GLP-1 access. If 10M people lose Medicaid, they lose GLP-1 coverage precisely when prices are becoming more accessible. The coverage loss and price compression are moving in opposite directions for the US population that most needs GLP-1s.
+
+**KB connections:**
+- Directly challenges: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — needs geographic and timeline scoping
+- Reinforces March 16 session finding: even at lower prices, GLP-1 without exercise = placebo for durability
+- Cross-domain: Rio should evaluate whether the GLP-1 patent cliff creates any internet-finance mechanisms for health access funding
+- The OBBBA/GLP-1 access contradiction: US prices will remain protected through 2031-2033 while Medicaid access is being cut — the population losing coverage is the one that can't afford the current $1,300/month price
+
+**Extraction hints:** TWO distinct claims: (1) GLP-1 international price compression is a 2026-2028 event, not 2030+ (challenges existing KB claim); (2) The OBBBA/GLP-1 coverage-price contradiction — coverage loss and price compression are moving in opposite directions for the US low-income population.
+
+## Curator Notes
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: Direct challenge to existing KB claim — patent expiration is happening NOW (India: March 20, 2026), not in 2030+. The "inflationary through 2035" claim needs geographic scoping at minimum and may be fundamentally wrong at the system level.
+EXTRACTION HINT: Extractor should propose a scope qualification or replacement for the existing GLP-1 claim, distinguishing US (patent-protected through 2031-2033) from international (price compression beginning 2026) and system-level (inflationary) from risk-bearing payer level (potentially deflationary by 2028-2030).